clinical trial · NCT02065011
A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B
Usher's SyndromeBlood draw for the laboratory assessment
brief summary
Primary Objective: To evaluate the long-term safety and tolerability of SAR421869 in patients with Usher syndrome Type 1B Secondary Objective: To assess long-term safety and biological activity of SAR421869
started
Sep 12, 2013
primary completion
Jun 13, 2031
completion
Jun 13, 2031
last updated
Jan 13, 2026
detailed description
The total duration of study period is up to 15 years.
official title
An Open-label Study to Determine the Long-term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol